Skip to main content
Bionano Genomics, Inc. logo

Bionano Genomics, Inc. — Investor Relations & Filings

Ticker · BNGO ISIN · US09075F1075 LEI · 54930086AP7ROH0VJ631 US Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2026-06-05 Board/Management Inform…
Country US United States of America
Listing US BNGO

About Bionano Genomics, Inc.

https://bionano.com/

Bionano Genomics is a life sciences company specializing in genome analysis. Its core technology, Optical Genome Mapping (OGM), provides high-resolution, genome-wide detection of all classes of structural variants (SVs), which are often missed by traditional sequencing and cytogenetic methods. The company offers an integrated workflow that includes the Ionic® system for DNA isolation, the Saphyr® and Stratys™ systems for OGM data generation, and the VIA™ software platform. The VIA software uniquely integrates and visualizes data from OGM, next-generation sequencing (NGS), and microarrays for comprehensive genomic interpretation. Bionano's solutions are used by researchers and clinicians in applications including oncology, genetic diseases, cell bioprocessing quality control, and cytogenomics.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 90% confidence The document is a Form 8-K Current Report under Item 5.02 announcing the resignation of the Chief Medical Officer, which is a management change announcement. This falls under Board/Management Information (MANG).
2026-06-05 English
8-K
Capital/Financing Update Classification · 90% confidence The document is a Form 8-K current report filed under the Securities Exchange Act reporting the full repayment (extinguishment) of the company’s Senior Secured Convertible Debentures and termination of associated liens. This constitutes a material capital structure change (debt financing activity), which fits the definition of a Capital/Financing Update (CAP) rather than a general regulatory or annual report filing.
2026-05-28 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a U.S. SEC Form 8-K Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing the final voting results for proposals at the 2026 Annual Meeting of Stockholders, including election of directors, advisory vote on compensation, and auditor ratification. This precisely matches the definition of a declaration of voting results at a general meeting (AGM).
2026-05-14 English
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
Earnings Release Classification · 90% confidence The document is a U.S. SEC Form 8-K filed under Item 2.02 “Results of Operations and Financial Condition,” reporting or furnishing the company’s first quarter financial results via a press release (Exhibit 99.1). This corresponds to an initial earnings announcement rather than full-period financial statements, making it an Earnings Release (ER). Q1 2026
2026-05-13 English
S-3 - Bionano Genomics, Inc. (0001411690) (Filer)
Capital/Financing Update Classification · 85% confidence The document is a Form S-3 registration statement filed with the U.S. Securities and Exchange Commission, providing a prospectus to register up to $400 million of various securities (common stock, preferred stock, debt, warrants, and units) under the Securities Act of 1933. This is clearly a financing document related to capital raising activities rather than an operational report, audit, or management announcement. It therefore fits the “Capital/Financing Update” category (CAP).
2026-05-08 English
DEF 14A - Bionano Genomics, Inc. (0001411690) (Filer)
Proxy Solicitation & Information Statement
2026-04-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.